New Therapies in the Treatment of Breast Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 9, 2006, Pages 3-8

  Roy, Vivek ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEMCITABINE; IMATINIB; IXABEPILONE; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; VINFLUNINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; CONSTIPATION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MONOTHERAPY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; VINBLASTINE;

EID: 33745208488     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.018     Document Type: Article

References (52)

1. Surveillance, Epidemiology, and End Results (SEER) Database. Available at: http://www.seer.cancer.gov/statfacts/html/breast.html (accessed April 27, 2006)
2. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
3. Ingle J., Rowland K., Suman V., et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy. A phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 88 (2004) 409 abstr
4. Jelovac D., Macedo L., Goloubeva O., et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65 (2005) 5439-5444
5. Aun B., Dice K., Albarracin C., et al. The combination of letrozole and imatinib mesylate for metastatic breast cancer. Breast Cancer Res Treat 88 (2004) 6046 abstr
6. Awada A., Cardoso F., Fontaine C., et al. A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. Breast Cancer Res Treat 88 (2004) 6043 abstr
7. Chu Q., Cianfrocca M., Murray N., et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. Breast Cancer Res Treat 88 (2004) 6044 abstr
8. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. Phase III trial results. J Clin Oncol 20 (2002) 2812-2823
9. Albain K., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC). First report of overall survival. Proc Am Soc Clin Oncol 22 (2004) 510 abstr
10. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (2005) 5542-5551
11. Perez E.A., Hillman D.W., Stella P.J., et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 88 (2000) 124-131
12. Perez E.A., Suman V.J., Fitch T.R., et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer. NCCTG study N9932. Oncology 69 (2005) 117-121
13. Decatris M.P., Sundar S., and O'Byrne K.J. Platinum-based chemotherapy in metastatic breast cancer. Current status. Cancer Treat Rev 30 (2004) 53-81
14. Perez E.A. Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 4 suppl 3 (2004) S113-S116
15. Sparreboom A., van Zuylen L., Brouwer E., et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. Clinical pharmacokinetic implications. Cancer Res 59 (1999) 1454-1457
16. John T.A., Vogel S.M., Tiruppathi C., et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284 (2003) L187-L196
17. Ibrahim N.K., Samuels B., Page R., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23 (2005) 6019-6026
18. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
19. Lee F.Y.F., Borzilleri R., Fairchild C.R., et al. BMS-247550. A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
20. Low J.A., Wedam S.B., Lee J.J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B Analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 (2005) 2726-2734
21. Bennouna J., Campone M., Delord J., et al. Vinflunine. A novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs 14 (2005) 1259-1267
22. Fumoleau P., Campone M., Vorobiof D., et al. Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. Proc Am Soc Clin Oncol 22 (2004) 542 abstr
23. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
24. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
25. Miller K., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. A trial coordinated by the Eastern Cooperative Oncology Group (E2100) (2003) Proceedings from the 28th annual San Antonio Breast Cancer Symposium. (abstr 3)
26. Dupont J., Schwartz L., Koutcher J., et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 22 (2004) 3009 abstr
27. Dupont J., Rothenberg M.L., Spriggs D.R., et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. Proc Am Soc Clin Oncol 23 (2005) 3029 abstr
28. Miller K.D., Burstein H.J., Elias A., et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 23 (2005) 563 abstr
29. Suttle A.B., Hurwitz H., Dowlati A., et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc Am Soc Clin Oncol 22 (2004) 3054 abstr
30. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
31. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
32. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
33. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
34. Baselga J., Carbonell X., Castaneda-Soto N.-J., et al. Updated efficacy and safety analyses of 3-weekly Herceptin monotherapy in women with HER2-positive metastatic breast cancer. Results from twelve months of follow-up to a phase II study. Breast Cancer Res Treat 88 (2004) 3042 abstr
35. O'Shaughnessy J.A., Vukelja S., Marsland T., et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5 (2004) 142-147
36. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer. multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
37. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 (2004) 739-749
38. Agus D.B., Gordon M., Taylor C., et al. Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc Am Soc Clin Oncol 22 (2003) 192 abstr
39. Attard G., Kitzen J.J., de Bono J., et al. A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 23 (2005) 3166 abstr
40. Cortes J., Baselga J., Kellokumpu-Lehtinen K., et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. Proc Am Soc Clin Oncol 23 (2005) 3068 abstr
41. Burris III H.A. Dual kinase inhibition in the treatment of breast cancer. Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 suppl 3 (2004) 10-15
42. Gomez H., Chavez M., Doval D., et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 23 (2005) 3046 abstr
43. Moore M., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 23 (2005) 1 abstr
44. Graham D., Hillman D., Hobday T.J., et al. N0234. Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 23 (2005) 644 abstr
45. Johnston S.R., Hickish T., Ellis P., et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21 (2003) 2492-2499
46. Ellis C.A., Vos M.D., Wickline M., et al. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78 (2003) 59-67
47. Johnston S.R., Head J., Pancholi S., et al. Integration of signal transduction inhibitors with endocrine therapy. An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9 (2003) 524-532
48. Lebowitz P.F., Eng-Wong J., Widemann B.C., et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res 11 (2005) 1247-1252
49. Wilhelm S., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
50. Yu K., Toral-Barza L., Discafani C., et al. mTOR, a novel target in breast cancer. The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8 (2001) 249-258
51. Carraway H., and Hidalgo M. New targets for therapy in breast cancer. Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6 (2004) 219-224
52. Chan S., Scheulen M., Johnston S., et al. Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens. Proc Am Soc Clin Oncol 22 (2003) 193 abstr